Supernus Pharmaceuticals | SUPN - Sales Revenues


Supernus Pharmaceuticals reported $211.6M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025